Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome by Koelzer, Viktor H et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome
Koelzer, Viktor H; Steuer, Karl; Gross, Ulrike Camenisch; Zimmermann, Dieter; Paasinen-Sohns, Aino;
Mertz, Kirsten D; Cathomas, Gieri
Abstract: BACKGROUND Personalized therapy of colorectal cancer is influenced by morphological,
molecular, and host-related factors. Here, we report the comprehensive clinicopathological and molecular
analysis of an extra-gestational colorectal choriocarcinoma in a patient with probable Lynch syndrome.
CASE PRESENTATION A 61-year-old female with history of gastric cancer at age 36 presented with
a transmurally invasive tumor of the right hemicolon and liver metastasis. A right hemicolectomy was
performed. Histopathological analysis showed a mixed trophoblastic and syncytiotrophoblastic differen-
tiation, consistent with choriocarcinoma. Disease progression was rapid under oxaliplatin, capecitabine,
irinotecan, and bevacizumab. Molecular phenotyping identified loss of mismatch-repair protein immunos-
taining for PMS2, microsatellite instability, a lack of MLH1 promoter methylation, and lack of BRAF
mutation suggestive of Lynch syndrome. Targeted next-generation sequencing revealed an ataxia telang-
iectasia mutated (p.P604S) missense mutation. A bleomycin, etoposide, and cisplatin treatment protocol
targeting germ cell neoplasia lead to disease remission and prolonged survival of 34 months. CONCLU-
SION Comprehensive immunohistochemical and genetic testing is essential to identify uncommon cancers
possibly related to Lynch syndrome. For rare tumors, personalized therapeutic approaches should take
both molecular and morphological information into account.
DOI: 10.3389/fonc.2016.00252
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-129105
Veröffentlichte Version
 
 
Originally published at:
Koelzer, Viktor H; Steuer, Karl; Gross, Ulrike Camenisch; Zimmermann, Dieter; Paasinen-Sohns, Aino;
Mertz, Kirsten D; Cathomas, Gieri (2016). Colorectal Choriocarcinoma in a Patient with Probable Lynch
Syndrome. Frontiers in Oncology, 6:252. DOI: 10.3389/fonc.2016.00252
November 2016 | Volume 6 | Article 2521
Case RepoRt
published: 29 November 2016
doi: 10.3389/fonc.2016.00252
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Tiziana Venesio, 
Istituto per la Ricerca e la Cura del 
Cancro (IRCC), Italy
Reviewed by: 
Gisela Keller, 
Technische Universität München, 
Germany  
Daniela Furlan, 
University of Insubria, Italy
*Correspondence:
Viktor H. Koelzer  
vkoelzer@gmail.com;
Gieri Cathomas  
gieri.cathomas@ksbl.ch
Specialty section: 
This article was submitted to 
Gastrointestinal Cancers, 
a section of the journal 
Frontiers in Oncology
Received: 30 July 2016
Accepted: 11 November 2016
Published: 29 November 2016
Citation: 
Koelzer VH, Steuer K, Gross UC, 
Zimmermann D, Paasinen-Sohns A, 
Mertz KD and Cathomas G (2016) 
Colorectal Choriocarcinoma in a 
Patient with Probable Lynch 
Syndrome. 
Front. Oncol. 6:252. 
doi: 10.3389/fonc.2016.00252
Colorectal Choriocarcinoma  
in a patient with probable Lynch 
syndrome
Viktor H. Koelzer1,2*, Karl Steuer3, Ulrike Camenisch Gross4, Dieter Zimmermann4,  
Aino Paasinen-Sohns1, Kirsten D. Mertz1 and Gieri Cathomas1*
1 Cantonal Hospital Baselland, Institute of Pathology, Liestal, Switzerland, 2 Translational Research Unit (TRU), Institute of 
Pathology, University of Bern, Bern, Switzerland, 3 Radio Onkologie Allschwil, Allschwil, Switzerland, 4 Division of Diagnostic 
Molecular Pathology, University Hospital Zürich, Zürich, Switzerland
Background: Personalized therapy of colorectal cancer is influenced by morphological, 
molecular, and host-related factors. Here, we report the comprehensive clinicopathologi-
cal and molecular analysis of an extra-gestational colorectal choriocarcinoma in a patient 
with probable Lynch syndrome.
Case presentation: A 61-year-old female with history of gastric cancer at age 36 
presented with a transmurally invasive tumor of the right hemicolon and liver metastasis. 
A right hemicolectomy was performed. Histopathological analysis showed a mixed 
trophoblastic and syncytiotrophoblastic differentiation, consistent with choriocarcinoma. 
Disease progression was rapid under oxaliplatin, capecitabine, irinotecan, and bevaci-
zumab. Molecular phenotyping identified loss of mismatch-repair protein immunostain-
ing for PMS2, microsatellite instability, a lack of MLH1 promoter methylation, and lack 
of BRAF mutation suggestive of Lynch syndrome. Targeted next-generation sequencing 
revealed an ataxia telangiectasia mutated (p.P604S) missense mutation. A bleomycin, 
etoposide, and cisplatin treatment protocol targeting germ cell neoplasia lead to disease 
remission and prolonged survival of 34 months.
Conclusion: Comprehensive immunohistochemical and genetic testing is essential 
to identify uncommon cancers possibly related to Lynch syndrome. For rare tumors, 
personalized therapeutic approaches should take both molecular and morphological 
information into account.
Keywords: colorectal cancer, choriocarcinoma, Lynch syndrome, microsatellite instability, ataxia telangiectasia 
mutated, molecular pathology, next-generation sequencing, personalized medicine
Abbreviations: β-HCG, beta human gonadotropin; AFP, alpha-fetoprotein; BEP, bleomycin, etoposide, and cisplatin; CD, 
cluster of differentiation; CIMP, CpG-island methylator phenotype; CK, cytokeratin; CRC, colorectal cancer; CT, computed 
tomography; DFS, disease-free survival; EGFR, epidermal growth factor receptor; NGS, next-generation sequencing; OS, 
overall survival; PLAP, placental alkaline phosphatase; UICC, International Union for Cancer Control; WHO, World Health 
Organization; XELOXIRI, oxaliplatin, capecitabine, irinotecan.
FIGURe 1 | Radiographic findings. (a) CT image of the lower abdomen 
showing a poorly delineated, partially necrotic tumor in the ileocecal region 
with a maximum diameter of 9.6 cm. (B) CT scan of the upper abdomen 
demonstrating hepatic metastases in segments II, VII, and VIII with a 
maximum diameter of 2.6 cm (segment VI not visible in this image plane).  
(C) Follow-up examination 24 months later showing subtotal regression of 
the metastases in segments VII and VIII and total regression of the lesion in 
segment II.
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BaCKGRoUND
Colorectal cancer (CRC) ranks among the three most com-
monly diagnosed malignant tumors worldwide according to the 
World Health Organization (WHO) (1). Importantly, CRC is a 
heterogeneous disease with different molecular subtypes, vari-
able clinical course, and prognosis. Optimal treatment requires 
comprehensive characterization of these features. Research to 
further develop the histopathological, molecular, and genetic 
characterization of CRC therefore builds essential knowledge to 
improve cancer therapy and survival.
The current gold standard to define CRC prognostic groups 
is the tumor node metastasis (TNM) classification published 
by the International Union for Cancer Control (UICC) (2). 
Extensive efforts have been made to aid the projection of post-
operative survival and treatment response based on molecular 
alterations (3). Adverse molecular markers include BRAF 
mutations found in approximately 10% of patients and the CpG-
island methylator phenotype (4, 5). KRAS and NRAS mutations 
correlate with poor response to drugs inhibiting the epidermal 
growth factor receptor (EGFR) (6). Microsatellite instability 
(MSI) is identified in 15–20% of CRC cases and is associated 
with favorable prognosis due to an increased anti-tumoral host 
immune response (7). Approximately 80% of MSI CRC arise 
in the sporadic setting due to hypermethylation of the MLH1 
gene, while 20% are associated with germline mutations of the 
mismatch-repair (MMR) genes, such as MLH1, PMS2, MSH6, 
or MSH2, in Lynch syndrome. Patients without an identified 
germline defect in a DNA MMR gene but with MSI and loss of 
MMR protein expression are likely to have Lynch syndrome if 
other causes of MSI, such as methylation of the MLH1 promoter, 
are excluded (8). The suggested WHO terminology for these 
cases is “probable Lynch syndrome” (8). However, recent studies 
indicate that pathogenic somatic mutations in MMR genes can 
also underlie the development of MSI in a subset of cases of early 
onset CRC (9–11). This group of cases has been termed “Lynch-
like” to underline the similar clinicopathological presentation 
with Lynch syndrome in absence of a proven germline-cause for 
MMR deficiency (12).
While the clinicopathological and molecular features of 
sporadic and hereditary CRC have been extensively studied, 
little is known about the occurrence of rare histopathological 
variants such as colorectal choriocarcinoma. Choriocarcinoma is 
a highly malignant neoplasm with trophoblastic differentiation. 
Gestational choriocarinoma most frequently occurs as a result 
of a molar pregnancy in pre-menopausal women and represents 
the vast majority of cases (13). Non-gestational choriocarcinoma 
can present as a component of ovarian and testicular germ cell 
tumors, while non-gestational, extra-gonadal choriocarcinomas 
are exceedingly rare (14). Discrimination of these forms of 
trophoblastic malignancy is of central importance as significant 
differences in the genetic origin, oncogenic driver mutations, 
immunogenicity, and sensitivity to chemotherapy exist (15). In 
particular, frequent targetable molecular alterations have been 
described in gestational disease, including an activation of the 
mitogen-activated kinase pathway (MAPK) through mutations 
in KRAS and BRAF oncogenes, overexpression of c-MYC, EGFR 
mutations, and activation of the mammalian target of rapamycin 
(mTOR) signaling network (16).
In adenocarcinomas of the gastrointestinal tract, choriocarci-
nomatous differentiation can take several forms. This ranges from 
the presence of individual beta human gonadotropin (β-HCG) 
positive malignant syncytiotrophoblastic giant cells in poorly 
differentiated adenocarcinoma over mixed tumors to pure cho-
riocarcinoma (14). Previous genetic analyses have highlighted a 
superimposed pattern of genetic changes in adeno- and chorio-
carcinoma components of mixed tumors suggesting a common 
stem cell origin (17). However, the molecular pathogenesis and 
presence of targetable mutations in extra-gestational disease 
has remained obscure. MMR deficiency and MSI in colorectal 
choriocarcinoma have not been previously identified. Here, we 
report the comprehensive morphological, immunohistochemi-
cal, and molecular analysis of a colorectal choriocarcinoma in a 
patient with probable Lynch syndrome.
Case pReseNtatIoN
A 61-year-old Caucasian post-menopausal female with a his-
tory of stage I signet ring cell carcinoma of the stomach at age 
36 was evaluated for a change in bowel habits and abdominal 
discomfort. There was a known family history of breast cancer in 
a second degree relative (aunt). Physical examination discovered 
a palpable resistance in the lower right quadrant. Colonoscopy 
identified a large stenosing mass in the cecum. An endoscopic 
biopsy was performed showing a poorly differentiated carcinoma 
with extensive necrosis. Computed tomography (CT) imaging 
confirmed the diagnosis of a 9.6-cm cecal mass (Figure 1A) and 
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identified four hepatic metastases with a maximum diameter of 
2.6 cm (Figure 1B). There was no evidence of a lesion involving 
the ovaries, the uterus, or a locoregional recurrence of gastric 
carcinoma. A right hemicolectomy with primary end-to-end 
anastomosis was performed. A diagnosis of primary colorectal 
choriocarcinoma in clinical stage IV was made. Pathological 
tumor stage according to the UICC TNM classification, 7th edi-
tion (2) was pT4a, pN0 (0/29), cM1 (HEPAR), L0, V1, Pn0, G3, 
and R0. Laboratory examinations showed significantly elevated 
serum β-HCG levels of 70.173 IU/ml (internal reference <2 IU/
ml), a normal level of carcinoembryonic antigen (CEA; 1.9 μg/l; 
internal reference <5.0  μg/l), and CA19.9 (6.7  kU/l; internal 
reference <35 kU/l). The patient was first treated with oxalipl-
atin, capecitabine, irinotecan, and bevacizumab (XELOXIRI/
bevacizumab) for two cycles according to the standard protocols 
(18). Rapid radiographic progression of disease and increasing 
serum levels of β-HCG were recorded under treatment. The 
therapeutic strategy was therefore adapted toward bleomycin/
etoposide/cisplatin (BEP) which has shown efficacy in high-risk 
gestational and extra-gestational trophoblastic neoplasia (15). A 
partial remission [RECIST 1.1 (19)] with radiographic evidence 
of a decrease in the sum of the diameters of the hepatic lesions 
of over 50% and a decrease in serum β-HCG levels to 8 IU/ml 
(internal reference range <2  IU/ml) was documented. Close 
follow-up was maintained.
Fifteen months later, laboratory and radiographic evidence of 
intra-abdominal tumor progression with new peritoneal lesions 
was recorded. Third line therapy with five cycles of carboplatin 
and bleomycin was initiated, leading to stabilization of disease 
(Figure 1C). New peritoneal, splenic, uterine, ovarian, and rectal 
lesions were noted on follow-up studies 6  weeks later. Salvage 
therapy with ifosfamide and vinblastine was started leading to a 
partial remission [RECIST 1.1 (19)]. The patient recovered well 
and surgical tumor debulking was performed 2 months later with 
resection of peritoneal lesions, the rectosigmoid, spleen, and 
uterus. Following recovery, two cycles of paclitaxel monotherapy 
were administered. Further treatment was delayed as a result of 
an intravascular catheter infection. There was rapid progression 
of hepatic disease with hilar compression. New bone metastases 
were detected in the spinal column. Due to rapid deterioration, 
the patient was entered into best supportive care and deceased 
34 months after diagnosis. An autopsy was not performed.
GRoss patHoLoGY, HIstoLoGY,  
aND IMMUNoHIstoCHeMIstRY
Gross examination of the resection specimen showed a poorly 
marginated tumor localized to the cecum and terminal ileum 
with serosal perforation (Figure 2A). Histopathological analysis 
revealed a solid carcinoma consisting of a dimorphic population 
of syncytiotrophoblastic giant cells and mononucleate tropho-
blastic cells arranged in a plexiform pattern with transmural 
infiltration of the colonic wall (Figure 2B) and multifocal venous 
invasion. Immunohistochemical analysis demonstrated strong, 
diffuse cytoplasmic reactivity for pan-cytokeratin (pan-CK) and 
β-HCG, while stains for the intestinal transcription factor CDX2 
were negative (Figure 3, top). Additional analyses of oncogenes 
associated with choriocarcinomatous differentiation revealed an 
overexpression of p53, the p53-associated protein MDM2 (not 
shown), c-MYC, and p16. Immunohistochemical analysis of the 
MMR proteins MLH1, PMS2, MSH6, and MSH2, showed an iso-
lated loss of PMS2 protein (Figure 3, bottom right). Antibodies 
used for immunohistochemical analysis and staining protocols 
are provided in Table 1.
MICRosateLLIte aNaLYsIs aND  
NeXt-GeNeRatIoN seQUeNCING
Based on a previous history of gastric cancer at age 36 and an iso-
lated loss of PMS2 protein expression by immunohistochemistry, 
the suspicion of Lynch syndrome was raised. This was further 
investigated by molecular studies of both tumors (Figure  4A). 
MSI analysis of the colorectal tumor showed shifted alleles in 
seven out of the nine microsatellite markers by multiplex PCR 
assay and high-resolution gel electrophoresis (instable: Bat-25, 
Bat-26, D2S123, D17S250, Bat-40, D13S153, D18S58; stable: 
D5S346, D10S197) (Figure  4B). This finding was consistent 
with an MSI-high genotype. The tumor MLH1 promoter region 
was un-methylated as revealed by bisulfite sequencing analysis 
(Figure 4C). Sequencing of BRAF hotspot regions in codons 600 
and 601 showed no mutations. Using archival material of the 
gastric primary from 1985, analysis of six microsatellite markers 
(Bat-25, Bat-26, D2S123, D5S346, D10S197, and D18S5) was 
successful. All markers were stable, and there was no evidence 
of MSI. In consistency with these findings, we found maintained 
expression of MLH1, PMS2, MSH6, and MSH2 in the gastric 
carcinoma by immunohistochemistry. No BRAF mutations 
were identified. MLH1 promoter methylation analysis was not 
performed. Germline mutation analysis of the PMS2 gene was 
not possible due to applicable legal regulations.
To further expand the molecular characterization of colorectal 
choriocarcinoma, two independent targeted next-generation 
sequencing (NGS) assays (Oncomine™ Focus Assay and Ion 
AmpliSeq™ Cancer Hotspot Panel v2, both from Thermo Fischer 
Scientific, Waltham, MA, USA) were performed according to 
the manufacturer’s instructions. The Oncomine™ Focus Assay 
allows the concurrent analysis of DNA and RNA for detection 
of mutations, copy number variations, and gene fusions in a 
comprehensive panel of clinically actionable oncogenic driver 
genes (21). The Ion AmpliSeq™ Cancer Hotspot Panel allows 
the identification of somatic mutations in a 50 gene panel (22). 
For NGS analysis, all diagnostic slides of a given case were re-
reviewed and representative blocks of formalin-fixed paraffin-
embedded material with a tumor cell content exceeding 80% were 
selected. Areas of necrosis were excluded. Microdissection was 
not performed. Identical analyses were carried out using archival 
material of the gastric primary from 1985. While no relevant 
molecular alterations were identified by the Oncomine™ Focus 
Assay in the colorectal choriocarcinoma, targeted NGS using 
the Ion AmpliSeq™ Cancer Hotspot Panel revealed an ataxia 
telangiectasia mutated (ATM p.P604S) mutation both in the 
primary tumor and metastatic lesions at an allele frequency of 
FIGURe 2 | Macroscopic and histopathological images. (a) Gross images showing a hemorrhagic and partially necrotic tumor with transmural infiltration of the 
colonic wall. (B) Histologic images showing a dimorphic population of syncytiotrophoblastic giant cells (arrows) and mononucleate trophoblastic cells arranged in a 
plexiform pattern invading the colonic wall with extensive hemorrhagic necrosis (left, 100×). Trophoblastic cells have ample eosinophilic cytoplasm and show 
markedly atypical nuclei with irregular nuclear membranes, coarse chromatin, and a single, prominent nucleolus. Syncytiotrophoblastic cells (arrows) have multiple 
nuclei with variable size and abundant eosinophilic to amphiphilic cytoplasm (right, 250×). Cytoplasmic vacuolization and lacunae are frequently observed.
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51.48 and 57.32%, respectively. An identical ATM p.P604S muta-
tion was identified in the gastric primary from 1985 with an allele 
frequency of 77.2%.
DIsCUssIoN
Clinical and therapeutic aspects
The present study underlines the importance of an integrative 
assessment of tumor morphology and molecular factors for opti-
mal management of rare tumors. Little is known about the natural 
history of colorectal choriocarcinoma as only 20 cases have been 
previously described with variable therapeutic interventions 
(14, 23, 24). Disease progression is generally rapid with early and 
aggressive metastasis. Response to adjuvant chemotherapy fol-
lowing surgical resection is poor, and disease-specific survival is 
commonly less than 1 year after diagnosis (14). A previous study 
identified responsiveness to oxaliplatin/fluorouracil/folinic acid 
(mFOLFOX6) and bevacizumab using an in vitro drug sensitivity 
test; however, therapeutic benefit was limited (14). In the present 
case, rapid progression of disease was observed under XELOXIRI/
bevacizumab leading us to change the treatment strategy toward 
the BEP regimen for germ cell neoplasia. We observed a rapid 
clinical response with a drop of serum β-HCG levels from 70.173 
to 8 IU/ml and a partial remission of metastatic lesions. However, 
other authors report limited efficacy of BEP in cases of colorectal 
choriocarcinoma (14, 24). A possible explanation for this dif-
ferential therapeutic response may be due to different variants 
of colorectal choriocarcinoma ranging from mixed tumors with 
a component of conventional intestinal adenocarcinoma to pure 
trophoblastic neoplasia (14, 24). Interestingly, a combined treat-
ment regimen targeting both components has previously shown 
efficacy in a case of mixed colorectal choriocarcinoma leading to 
long-term disease-free survival of 60 months (25). This suggests 
taBLe 1 | antibodies used for immunohistochemical analysis and 
staining protocols.
antibody Company Clone pretreatmenta Dilution
MLH1 BD Biosciences G168-15 H2 (30 min) 100°C 1:25
PMS2 BD Biosciences A16-4 H2 (30 min) 95°C 1:200
MSH2 BD Biosciences 27 H2 (20 min) 95°C 1:400
MSH6 BD Biosciences 44 H2 (30 min) 100°C 1:200
panCK Biomedicals Lu5 Enzyme 1 (5 min) 1:400
β-hCG Dako Polyclonal H2 (20 min) 100°C 1:32,000
CDX2 Cellmarque EPR2764Y H2 (20 min) 95°C 1:200
p53 Dako D07 H1 (20 min) 100°C 1:2,400
c-Myc Origene Y69 H2 (40 min) 100°C 1:25
p16 CINtec Ink4a H1 (20 min) 100°C 1:1 (pre-diluted)
MDM2 Invitrogen IF2 H2 (30 min) 95°C 1:200
aAll stains were performed on a Leica BOND III/max autostainer platform (Leica 
Bioystems, Muttenz, Switzerland) according to the standard protocols. Detection 
system: Bond Polymer Refine Red Detection (Leica Biosystems); Counterstain: 
Hemalum.
FIGURe 3 | protein expression profiling by immunohistochemistry. Immunohistochemical stains (from left to right, top to bottom) showing diffuse, strong 
cytoplasmic reactivity of the neoplastic cell population for pan-CK. β-HCG stain highlights syncytiotrophoblastic giant cells (all 400×). No expression of CDX2 was 
observed in the tumor cells; note the normal colonic epithelium in the upper left corner (40×). Analysis of postulated oncogenes revealed strong overexpression of 
p53, c-MYC, and p16. The neoplastic cell population showed an isolated loss of PMS2, while MLH1 was maintained; note the positively stained tumor infiltrating 
lymphocytes (all 400×).
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that histological tumor composition could be a potential indica-
tor of treatment response.
Remarkably, review of clinicopathological data shows that 
9 of the 21 previously reported cases of colorectal choriocarci-
noma have arisen in patients under 50 years of age (23, 24). This 
precedes the median age of CRC diagnosis in western countries 
by about two decades (26). These data may suggest a possible 
association of colorectal choriocarcinoma with hereditary 
cancer syndromes. Indeed, one case of colorectal choriocarci-
noma has been previously identified in a patient with juvenile 
polyposis (23). No specific investigations were reported in the 
remaining cases, leading to a possible underidentification of 
patients with hereditary disease. The unusual presentation of 
colorectal choriocarcinoma at a young age and the possible 
contribution of background genetic factors therefore require 
further investigation. In particular, Lynch syndrome may be 
easily missed if screening for MMR protein expression or MSI 
testing is not performed (27). Importantly, MSI is also a strong 
favorable prognostic indicator in CRC patients (28). Although 
the prognostic impact of MSI in colorectal choriocarcinoma is 
presently unknown, this factor may have favorably influenced 
the prognosis in the present case.
Molecular pathology
DNA mismatch repair is initiated by formation of the DNA-
repair complex involving both MSH and MLH heterodimers 
(29). In sporadic MSI CRC, loss of MLH1 expression is caused 
by promoter methylation of the MLH1 gene (30). As MLH1 
protein is essential for stabilization of PMS2, MLH1 deficiency 
in sporadic MSI CRC is usually associated with loss of PMS2 
expression (31). A further common genetic hallmark of 
sporadic MSI CRC is the presence of BRAF V600E mutation 
(32). In contrast, an isolated loss of PMS2 expression is a strong 
indicator of germline mutations in PMS2 or MLH1 in Lynch 
syndrome patients (33). Although we were unable to provide the 
ultimate proof of an MMR germline mutation in the present case 
due to legal restrictions, the classification as a probable Lynch 
syndrome is strongly supported by a lack of MLH1 promoter 
methylation and lack of BRAF mutation as well as isolated loss of 
PMS2 protein expression (8, 33, 34). PMS2 mutations are associ-
ated with a lower penetrance and variable clinical phenotypes 
ranging from early- or late-onset to apparently sporadic CRC (8, 
35). The cumulative CRC risk of female PMS2 mutation carriers 
by age 70 has been estimated as low as 11% for CRC in a recent 
FIGURe 4 | Molecular analysis. (a) Flowchart of molecular analysis. (B) Representative image of high-resolution capillary gel electrophoresis (QIAxcel high-
resolution cartridge, QIAGEN AG, Hombrechtikon, Switzerland) of microsatellite markers. One sample of normal tissue and one tumor sample was analyzed for each 
marker. Electropherograms showed shifted alleles in seven out of the nine analyzed markers in the choriocarcinoma tissue [Bat-25 (shown), Bat-26 (shown), 
D2S123 (shown), D17S250, Bat-40, D13S153, and D18S58] indicating high-grade microsatellite instability. Two out of the nine markers showed an identical 
fragment length between normal and tumor tissue [D5S346 (shown) and D10S197]. (C) Bisulfite sequencing. Sequence of the patient DNA sample in comparison to 
a reference non-methylated DNA (tonsil). Treatment of DNA with bisulfite converts cytosine residues to uracil. Methylated cytosine bases remain unaffected. The 
tumor MLH1 promoter region was un-methylated as is shown by comparison of the patients DNA with the reference sequence. Positions of cytosins best correlating 
with MLH1 expression are highlighted in yellow [numbering according to Deng et al. (20)].
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large European cohort study of 8 PMS2 families that included a 
total of 2,548 family members and 377 proven mutation carriers 
(36). Consequently, only 65.5% of patients with monoallelic 
PMS2 germline mutations may meet the revised Bethesda 
guidelines (37). The abovementioned study has also suggested 
an increased incidence of breast cancer in patients with PMS2 
germline mutations [standardized incidence ratio 3.8 (95% CI, 
1.9–6.8)], and there is a positive family history for this tumor in 
our patient (36). Still, the possibility of a Lynch-like syndrome 
with a somatic PMS2 gene mutation underlying the develop-
ment of MSI cannot be excluded as somatic mutation analysis 
of MMR genes was not performed (12). However, somatic MMR 
gene mutations are most frequently described in MLH1 and 
MSH2, while somatic PMS2 mutations are uncommon in CRC 
(9–11).
We performed a comprehensive screen for clinically action-
able mutations using two targeted NGS assays to analyze both 
the present colorectal tumor and the previously diagnosed 
gastric carcinoma from 1985 (21, 22). This approach identified 
an identical ATM p.P604S missense mutation with an allele 
frequency of up to 57.32% in the colorectal primary and 77.2% 
in the gastric tumor. ATM p.P604S falls into the N-terminal 
domain of the ATM gene leading to a C > T amino acid substitu-
tion at c.1810. On a population level, ATM p.P604S has been 
described as an infrequent polymorphism present in about 0.5% 
of the population with conflicting interpretations of pathogenic-
ity (38). While the determination of the impact of ATM p.P604S 
is beyond the scope of the present study, the assignment of this 
molecular alteration to a germline polymorphism seems likely 
considering the identification at high allele frequency in all 
analyzed samples.
Other studies have identified ATM p.P604S as a somatic muta-
tion in lymphoid neoplasms (39–41), but not in solid tumors. 
ATM p.P604S has been suggested by other authors to create a 
new glycosylation site which might interfere with ATM function 
and protein–protein interaction (42). In particular, ATM is an 
important stabilizer of the MMR protein complex during DNA 
repair (43) and induces p53 expression in response to DNA 
damage (44). Concomitant pathogenic ATM mutations and 
MMR deficiency in the setting of Lynch syndrome may therefore 
have further detrimental effects on genomic stability. Selective 
inhibitors of ATM are currently in preclinical development and 
may represent future options to treat tumors with defects in the 
DNA-damage response (45).
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